US Patent 9,284,280: Selexipag Crystal Patent Scope, Claims, Expiration and Generic Risk
US Patent 9,284,280 protects a specific crystalline form of selexipag, the active pharmaceutical ingredient in Uptravi. Its enforceable claims are method-of-treatment claims, not broad composition, formulation, manufacturing-process, or dosage claims. The patent is therefore strongest against use of the claimed crystal form in the listed diseases, particularly pulmonary hypertension, peripheral circulatory disease, pulmonary fibrosis, and chronic renal failure.
The patent was granted on March 15, 2016. Its nominal patent term is expected to extend into 2032, subject to the applicable patent-term adjustment and any regulatory exclusivity. The patent does not create biosimilar risk because selexipag is a chemically synthesized small molecule regulated through the ANDA pathway rather than the biosimilar pathway.
What drug and crystalline form does US 9,284,280 cover?
US 9,284,280 covers a crystal of selexipag identified by specific X-ray powder diffraction peaks. The chemical name in the claims is:
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide.
This compound is selexipag, marketed by Actelion Pharmaceuticals, a Johnson & Johnson company, as Uptravi for pulmonary arterial hypertension. The patent identifies the claimed crystal using Cu Kα X-ray powder diffraction and requires peaks at least at:
| Required diffraction angle |
2θ |
| Peak 1 |
9.4° |
| Peak 2 |
9.8° |
| Peak 3 |
17.2° |
| Peak 4 |
19.4° |
The claim is not limited to a particular tablet strength, excipient system, dosing schedule, route of administration, or manufacturing process. The crystal identity is the central technical limitation. (U.S. Patent No. 9,284,280, 2016)
What does claim 1 of US 9,284,280 require?
Claim 1 requires two elements:
- Administration of the specified selexipag crystal to a subject.
- Treatment of at least one disease or condition listed in the claim.
The listed conditions are:
- Diabetic neuropathy
- Diabetic gangrene
- Peripheral circulatory disturbance
- Chronic arterial occlusion
- Intermittent claudication
- Scleroderma
- Thrombosis
- Pulmonary hypertension
- Myocardial infarction
- Angina
- Glomerulonephritis
- Diabetic nephropathy
- Chronic renal failure
- Bronchial asthma
- Interstitial pneumonia, including pulmonary fibrosis
- Chronic obstructive pulmonary disease
- Inflammatory bowel disease
- Symptoms associated with spinal canal stenosis
Claim 1 is unusually broad in its disease list but narrow in its active-ingredient limitation. A product must contain the claimed crystalline form, and the accused use must fall within the claimed therapeutic categories.
The phrase “showing diffraction peaks ... at least” broadens the claim beyond a crystal exhibiting only four peaks. A crystal that shows the four required peaks, together with additional peaks, can fall within the literal language if the material is otherwise the claimed selexipag crystal. The claim does not require a precise intensity ratio, peak width, crystal habit, melting point, water content, or particle-size distribution.
How do claims 2 through 9 narrow the patent scope?
Claims 2 through 9 depend on claim 1 and limit the treatment indication.
| Claim |
Disease or condition |
| 1 |
Any listed disease or condition |
| 2 |
Peripheral circulatory disturbance |
| 3 |
Chronic arterial occlusion |
| 4 |
Intermittent claudication |
| 5 |
Scleroderma |
| 6 |
Pulmonary hypertension |
| 7 |
Pulmonary fibrosis |
| 8 |
Symptoms associated with spinal canal stenosis |
| 9 |
Chronic renal failure |
The dependent claims do not add a dose, formulation, regimen, patient subgroup, or administration route. Their primary legal effect is to create narrower fallback claims if claim 1 is invalid or not infringed.
Claim 6 is commercially important because pulmonary hypertension is the closest claimed condition to Uptravi’s approved use for pulmonary arterial hypertension. Claim 7 may create additional risk for products labeled or promoted for pulmonary fibrosis. Claims 2 through 5 and 8 through 9 are more relevant to off-label use, future indications, or inducement theories than to the current Uptravi label.
What is the technical scope of the crystal limitation?
The patent protects a solid-state form rather than merely the selexipag molecule. This distinction matters because chemically identical molecules can exist in multiple polymorphs, solvates, hydrates, amorphous forms, or mixtures.
A potentially infringing material would generally be evaluated through:
- Powder X-ray diffraction
- Comparison against an authenticated reference standard
- Solid-state characterization
- Thermal analysis
- Water or solvent content
- Microscopy and particle morphology
- Batch-to-batch consistency
The four listed peaks are necessary under the claim language, but a complete infringement analysis would normally compare the accused material against the full patent specification and validated analytical methods. Peak position tolerance, sample preparation, instrument calibration, and polymorphic mixtures can affect the result.
The patent does not expressly require:
- A particular polymorphic purity
- A single-crystal form
- A specific tablet formulation
- A specific dosage
- A specific route of administration
- A specific pharmacokinetic profile
- A particular combination therapy
This gives the patent flexibility against products using the claimed crystal in different formulations or strengths. It also creates potential design-around opportunities for a genuinely different solid form that does not exhibit the four required peaks.
What patents protect selexipag and Uptravi?
The selexipag patent estate includes multiple protection layers, with different commercial and legal functions.
| Protection layer |
Typical subject matter |
Relevance to generic entry |
| Compound patents |
Selexipag chemical structure and related derivatives |
Broadest molecular protection; generally earlier expiration |
| Crystal or polymorph patents |
Defined solid-state forms identified by XRPD or related properties |
Can extend product protection beyond compound patents |
| Formulation patents |
Tablets, excipients, release properties, or dosage forms |
Relevant to the marketed product and substitution |
| Method-of-use patents |
Treatment of pulmonary hypertension or other diseases |
Relevant to label strategy and induced infringement |
| Process patents |
Synthesis, purification, crystallization, or isolation |
Can create manufacturing barriers but may not block a different process |
| Regulatory exclusivity |
New-drug and pediatric exclusivity |
Independent of patent validity |
US 9,284,280 is principally a crystal and method-of-treatment patent. It is not a conventional composition-of-matter patent and does not claim every form of selexipag.
Other selexipag-related U.S. patents, including US 8,318,802 and US 8,598,227, have been associated publicly with the selexipag patent estate. Their precise claim scope, listing status, and expiration dates should be analyzed separately from US 9,284,280 because a generic product can face different infringement theories under each patent.
When does US 9,284,280 lose exclusivity?
The patent was granted on March 15, 2016. The relevant patent term is generally calculated from the applicable U.S. nonprovisional or international filing date, not simply from the grant date or the earliest foreign priority date. Based on the patent family chronology, the nominal term is expected to run into 2032.
| Event |
Date or period |
| Patent grant |
March 15, 2016 |
| Expected nominal patent-term horizon |
2032 |
| FDA approval of Uptravi |
December 21, 2015 |
| Regulatory pathway |
New drug application |
| Product type |
Chemically synthesized small molecule |
| Biosimilar pathway |
Not applicable |
The exact expiration date depends on the patent’s recorded filing date, patent-term adjustment, terminal disclaimer status, and any patent-term extension. FDA regulatory exclusivity is separate from the patent term. The New Chemical Entity exclusivity period associated with the original approval would not ordinarily extend to 2032, so the principal long-term barrier is patent protection rather than NCE exclusivity. (FDA, 2015; USPTO, 2024)
What is the Orange Book status of US 9,284,280?
US 9,284,280 has been associated with the Uptravi patent estate and is relevant to Orange Book analysis because its claims concern the approved active ingredient and pulmonary hypertension use. The practical significance depends on whether the patent is listed against the relevant Uptravi NDA and what FDA patent-use code is assigned.
An Orange Book listing can require an ANDA applicant to submit one of the following certifications:
- Paragraph I: No patent information has been submitted.
- Paragraph II: The listed patent has expired.
- Paragraph III: The applicant will not market until patent expiration.
- Paragraph IV: The listed patent is invalid, unenforceable, or will not be infringed.
If the listed use can be omitted from the proposed label, an applicant may consider a section viii statement for a method-of-use patent. That option is more difficult where the patent is tied to the product’s principal approved use or where the label still encourages use of the claimed crystal for pulmonary hypertension.
The Orange Book does not determine patent validity. It identifies patents submitted by the NDA holder and the use codes associated with those patents. (FDA, 2024)
What Paragraph IV challenges could target this patent?
A Paragraph IV challenge to US 9,284,280 could focus on invalidity, noninfringement, or both.
Potential noninfringement theories
A generic applicant could argue that:
- Its selexipag is a different polymorph.
- Its product is amorphous or contains a different hydrate or solvate.
- The required four XRPD peaks are absent.
- The product does not contain the claimed crystal at commercial scale.
- The proposed label omits a patented method of use.
- The applicant does not induce administration for a claimed disease.
The strongest noninfringement position would require reliable analytical evidence showing that the commercial product does not contain the claimed crystal, including as a result of manufacturing, storage, milling, granulation, or tableting.
Potential invalidity theories
A Paragraph IV applicant could challenge:
- Anticipation by an earlier selexipag crystal disclosure
- Obviousness based on prior-art crystallization work
- Inadequate written description
- Lack of enablement across the full claim scope
- Indefiniteness concerning the crystal identity or XRPD limitations
- Failure to distinguish the claimed form from known selexipag material
The “at least” diffraction language may become central to an indefiniteness or written-description dispute if the specification does not adequately define the boundaries of the claimed crystal.
What generic launch scenarios exist?
Three principal launch scenarios exist.
Scenario 1: Launch after patent expiration
The generic applicant accepts the patent and delays commercial launch until the patent term ends. This avoids Paragraph IV litigation but sacrifices first-filer economics and delays market entry.
Scenario 2: Paragraph IV litigation and at-risk launch
The applicant certifies that US 9,284,280 is invalid or not infringed. If the NDA holder sues within the statutory period, the ANDA approval may be subject to a 30-month stay, subject to statutory exceptions and court action. An at-risk launch may expose the applicant to damages, injunctive relief, and supply disruption.
Scenario 3: Different crystal or label carve-out
The applicant develops a non-infringing solid form and uses a label that omits patented indications where legally available. This strategy is technically difficult because the generic must maintain pharmaceutical equivalence and bioequivalence while avoiding the claimed XRPD profile.
The absence of a composition-of-matter claim in US 9,284,280 improves the theoretical design-around position. The commercial risk remains significant if other selexipag patents cover the molecule, formulation, or approved use.
Does selexipag face biosimilar risk?
No. Selexipag is a small-molecule active ingredient, not a biologic. The relevant challenge route is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A biosimilar application under section 351(k) of the Public Health Service Act is not applicable.
The competitive threat therefore comes from generic selexipag products, not biosimilars. Generic applicants must address pharmaceutical equivalence, bioequivalence, patent certifications, and any listed formulation or method-of-use patents.
What litigation and settlement issues affect US 9,284,280?
The patent text does not establish a litigation outcome, Paragraph IV filing, settlement, license, or covenant not to sue. A complete litigation assessment must distinguish among:
- District-court patent complaints
- ANDA litigation under the Hatch-Waxman framework
- Inter partes review proceedings
- Post-grant review
- Federal Circuit appeals
- Patent settlements and launch dates
- Licensing arrangements affecting particular territories
The commercial history of selexipag includes collaboration between Actelion and Nippon Shinyaku. Commercial collaboration does not by itself establish a license covering US 9,284,280, nor does it determine Orange Book ownership or enforcement rights. Patent assignments and recorded licenses must be reviewed separately from product-label information.
How strong is the patent estate for Uptravi?
US 9,284,280 is a meaningful secondary patent because it targets a specific crystalline form that can be used in the approved product. Its strength is higher if:
- The Uptravi active ingredient is consistently the claimed crystal.
- The patent is listed in the Orange Book.
- The specification provides strong analytical characterization.
- The NDA holder can prove crystal identity in commercial tablets.
- Other patents independently cover the molecule, formulation, or pulmonary hypertension use.
Its strength is lower if:
- A generic can use a distinct crystal form.
- The claimed peaks are common to multiple selexipag forms.
- The patent’s written description does not adequately support the breadth of the “at least” language.
- The principal approved indication is protected only by a narrow method claim.
- The patent expires after the primary compound protection but lacks enforceable complementary claims.
What geographic coverage does the patent provide?
US 9,284,280 has U.S. territorial effect. It does not directly block manufacture, use, sale, or importation outside the United States. Parallel protection may exist in other jurisdictions through the underlying international patent family, but foreign patents can differ in:
- Claim wording
- Validity
- Patent-term calculation
- Supplementary protection certificates
- Regulatory exclusivity
- Orange Book-equivalent listing systems
- Generic litigation procedures
A global launch analysis must therefore review the national family members separately. U.S. expiration does not establish expiration in Europe, Japan, Canada, or other markets.
Key Takeaways
- US 9,284,280 protects a defined selexipag crystal identified by XRPD peaks at 9.4°, 9.8°, 17.2°, and 19.4° 2θ using Cu Kα radiation.
- The patent contains method-of-treatment claims, not a broad chemical composition claim.
- Claim 1 covers multiple diseases, while claims 2 through 9 narrow the scope to specified indications.
- Pulmonary hypertension is the most commercially important claimed use because it corresponds to Uptravi’s approved therapeutic area.
- The patent does not cover every selexipag polymorph, amorphous form, hydrate, solvate, formulation, or manufacturing process.
- The nominal patent-term horizon is expected to extend into 2032, subject to the official USPTO term calculation.
- Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
- The principal design-around strategy is a genuinely different selexipag solid form combined with an appropriate label.
- Orange Book listing, patent-use codes, other selexipag patents, and any Paragraph IV litigation must be assessed together.
- Actelion/Janssen commercial rights and Nippon Shinyaku patent ownership or licensing interests should not be conflated without reviewing assignment and licensing records.
FAQs about US 9,284,280 and selexipag patent protection
Does US 9,284,280 cover all Uptravi tablets?
It can cover Uptravi tablets if the selexipag in those tablets is the claimed crystal and the tablets are administered for a claimed disease. The patent does not independently claim every Uptravi formulation.
Can a generic avoid US 9,284,280 by using amorphous selexipag?
Potentially. An amorphous product that does not show the required XRPD peaks may have a noninfringement position, but the product must also satisfy pharmaceutical-quality and bioequivalence requirements and avoid other applicable patents.
Is pulmonary arterial hypertension expressly named in claim 1?
The claim names “pulmonary hypertension,” which is broader than pulmonary arterial hypertension as a textual matter. The approved Uptravi indication is pulmonary arterial hypertension, making claim 6 particularly relevant.
Does this patent block selexipag manufacturing outside the United States?
No. The patent is a U.S. right. Foreign manufacturing may still create U.S. liability if the patented product is imported into, sold in, or used in the United States, subject to applicable statutory and extraterritoriality rules.
Is a Paragraph IV challenge to the crystal patent likely to involve laboratory testing?
Yes. The central infringement issue would usually require comparison of the proposed product’s solid-state form with the patented XRPD characteristics, including testing of representative commercial batches and the finished dosage form.
References
-
Food and Drug Administration. (2015). Uptravi (selexipag) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Patent No. 9,284,280. (2016). Crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide. United States Patent and Trademark Office.
-
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Patent certification and exclusivity provisions. U.S. Department of Health and Human Services.
